Table 6. Univariate and multivariate analyses of disease-free survival.
Variable | Category | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|---|
Hazard ratio | 95% CI | p value | Hazard ratio | 95% CI | p value | ||
Whole group | |||||||
T stage | T1 vs. T2-4 | 1.750 | 0.826–3.706 | 0.144 | 1.219 | 0.561–2.653 | 0.617 |
N stage | N0 vs. N1-3 | 2.468 | 1.147–5.311 | 0.021 | 2.715 | 1.254–5.875 | 0.011 |
Histologic grade | I vs. II & III | 5.099 | 0.694–37.488 | 0.109 | 4.247 | 0.570–31.626 | 0.158 |
LVI | Absent vs. Present | 2.735 | 1.245–6.008 | 0.012 | 1.984 | 0.840–4.687 | 0.118 |
Oct4 | Negative vs. Positive | 2.522 | 1.148–5.542 | 0.021 | 2.542 | 1.144–5.647 | 0.022 |
Hormone receptor-positive group | |||||||
T stage | T1 vs. T2-4 | 2.546 | 1.027–6.309 | 0.044 | 2.067 | 0.827–5.168 | 0.120 |
N stage | N0 vs. N1-3 | 3.606 | 1.320–9.852 | 0.012 | 4.443 | 1.613–12.236 | 0.004 |
Histologic grade | I vs. II & III | 5.533 | 0.742–41.246 | 0.095 | 2.789 | 0.352–22.089 | 0.331 |
LVI | Absent vs. Present | 2.167 | 0.874–5.374 | 0.095 | 1.053 | 0.398–2.786 | 0.918 |
Oct4 | Negative vs. Positive | 6.346 | 2.662–15.128 | <0.001 | 7.782 | 3.226–18.772 | < 0.001 |
Hormone receptor-positive group treated with tamoxifen | |||||||
T stage | T1 vs. T2-4 | 2.029 | 0.772–5.334 | 0.151 | 1.755 | 0.658–4.678 | 0.261 |
N stage | N0 vs. N1-3 | 2.847 | 1.003–8.083 | 0.049 | 3.729 | 1.291–10.769 | 0.015 |
Histologic grade | I vs. II & III | 3.246 | 0.430–24.504 | 0.254 | 1.434 | 0.175–11.720 | 0.737 |
LVI | Absent vs. Present | 1.443 | 0.549–3.792 | 0.457 | 0.912 | 0.336–2.477 | 0.857 |
Oct4 | Negative vs. Positive | 5.662 | 2.179–14.716 | <0.001 | 7.115 | 2.683–18.870 | < 0.001 |
P values were calculated by Cox proportional hazards regression model with a backward stepwise selection method.
CI, confidence interval; LVI, lymphovascular invasion.